Search results
American healthcare biotech venture capitalist
- Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. She focuses on investing in healthcare companies and early-stage biotech start-ups. She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY) and ByHeart, and represents Polaris as a director for Kallyope, Thirty Madison, QurAlis, and Larkspur.
en.wikipedia.org/wiki/Amy_Schulman
People also ask
Who is Amy Schulman?
Who is Amy Schultz?
Did Amy Schulman make mistakes?
Who is Emily Schuman?
Amy Schulman. Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. [1][2][3] She focuses on investing in healthcare companies and early-stage biotech start-ups. [2][4] She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY ...
Amy W. Schulman is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Ms. Schulman joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014.
Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. [1] [2] [3] She focuses on investing in healthcare companies and early-stage biotech start-ups.
Amy Schulman. Amy is a managing partner at Polaris Partners who focuses on investing in healthcare companies and early stage biotech start-ups. She serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and as chair of the Board of Directors of ByHeart.
Amy Schulman is a Managing Partner at Polaris Partners, a venture capital firm, and co-founder of the Polaris Innovation Fund. She currently serves as executive chair of Lyndra Therapeutics, which she co-founded and served as the company's initial CEO.
Nov 10, 2010 · Amy Schulman joined Pfizer two years ago as general counsel and led the legal team in the drug maker's $68 billion acquisition of Wyeth Pharmaceuticals in 2009. The National Law Journal named her ...
Jul 29, 2014 · Amy W. Schulman is an accomplished business leader, widely recognized for growing global businesses, demonstrating a commitment to people, and fostering inclusive workplace cultures. In July,...